Clinical efficacy of EGFR-TKIs for advanced squamous-cell lung cancer patients with EGFR mutations
-
摘要: 目的：探讨表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors，EGFR-TKIs）对具有表皮生长因子受体（epidermal growth factor receptor ，EGFR）突变的晚期肺鳞癌患者临床疗效。方法：回顾性分析首都医科大学附属北京胸科医院2010年1 月至2016年7 月收治的2 317 肺鳞癌患者，筛选出有明确随访记录的7 例确诊具有EGFR 突变的肺鳞癌患者，使用EGFR-TKI 如吉非替尼、厄洛替尼治疗，直至疾病进展（progressive disease ，PD）。 结果：使用EGFR-TKI 治疗后，患者客观缓解率（objectire response rate ，ORR ）42.9% ，疾病控制率（disease control rate ，DCR ）100%（7/ 7），中位无进展生存期6.1 个月。结论：EGFR-TKI 对EGFR 突变的肺鳞癌患者具有一定临床疗效。但本研究病例数少仅有7 例，亟需更多的病例来进行补充研究及验证上述结论。Abstract: Objective:To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs) in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods:We screened out seven patients who were diag-nosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from2,317 squamous-cell lung cancer patients treat -ed at the Beijing Chest Hospital from January 2010to July 2016. Results:After using EGFR TKIs, the objective response rate was42. 9%, the disease control rate was 100 % , and the median progression- free survival was6. 1 months.Conclusion: EGFR- TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous- cell lung cancer. However, given that only seven cases are pre -sented in this research group, more cases are needed for further research to verify the above conclusion.
-
-
期刊类型引用(2)
1. 李英，魏益群，薛智文，洪选平. 吉非替尼治疗肺鳞癌的效果及对患者CRP水平的影响. 临床医学研究与实践. 2019(20): 5-6 . 
百度学术
2. 李晓琳，赵月，马婧，冯妮，李国晖，陈维. 非小细胞肺癌肿瘤标志物联合检测在诊断中的意义及其对EGFR突变的预测价值. 肿瘤药学. 2019(04): 607-611 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 42
- HTML全文浏览量: 0
- PDF下载量: 7
- 被引次数: 3
下载:
